BioTuesdays

Category - Markets

Dicerna Logo

HCW starts Dicerna at buy

H.C. Wainwright initiated coverage of Dicerna Pharmaceuticals (NASDAQ:DRNA) with a “buy” rating and $7 price target. The stock closed at $3.05 on Dec. 12. Dicerna recently announced its intention to shift development of...

Nobilis Health

Craig-Hallum downgrades Nobilis to hold

Craig-Hallum downgraded Nobilis Health (NASDAQ:HLTH) to “hold” from “buy” and slashed its price target to $2 from $6. The stock closed at $2.25 on Dec. 12. Analyst Charles Haff attributed the downgraded to what he...

Concordia International

RBC downgrades Concordia Intl to underperform

RBC Capital Markets downgraded Concordia International (NASDAQ:CXRX; TSX:CXR) to “underperform” from “sector perform” and cut its price target to $1 from $2.50. The stock closed at $2.38 on Dec. 6. Britain’s Competition...

iRhythm Technologies

BTIG downgrades iRhythm to neutral

BTIG downgraded iRhythm Technologies (NASDAQ:IRTC) to “neutral” from “buy,” noting that the shares recently surpassed BTIG’s price target of $28 but have fallen $1.25 at midday Dec.6 to $27.98. “We are not making...

Neovasc Logo

Echelon ups Neovasc price target to $3.25

Echelon Wealth Partners raised its price target for Neovasc (NASDAQ:NVCN) to $3.25 from $1.25 after the company sold its PeriPatch processing operations to Boston Scientific (NYSE:BSX). The stock closed at 86 cents on...

Galena Biopharma

Maxim ups Galena Biopharma price target to $4

Maxim Group raised its price target for Galena Biopharma (NASDAQ:GALE) to $4 from $1, saying the company has multiple programs moving forward, including NeuVax. The stock was quoted at $2.90 in afternoon trading on Dec...

Stellar Biotechnologies

Maxim cuts Stellar price target to $4

Maxim Group reduced its price target for Stellar Biotechnologies (NASDAQ:SBOT) to $4 from $7, saying demand for the company’s keyhole limpet hemocyanin (KLH) is a slow climb. The stock was quoted at $2.59 at midday Dec...

Aradigm

Ladenburg cuts Aradigm price target to $7.50

Ladenburg Thalmann slashed its price target for Aradigm (NASDAQ:ARDM) to $7.50 from $26 but maintained its “buy” rating after the company reported mixed top-line Phase 3 results for Pulmaquin for the treatment of non...

Inotek Pharmaceuticals

Roth starts Inotek Pharma at buy

Roth Capital Partners initiated coverage of Inotek Pharmaceuticals (NASDAQ:ITEK) with a “buy” rating and $10 price target. The stock closed at $6.40 on Nov. 30. “In our opinion, Inotek’s trabodenoson has the...

Bellicum Pharmaceuticals

Ladenburg starts Bellicum Pharma at buy

Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals (NASDAQ:BLCM) with a “buy” rating and $31 price target. The stock closed at $19.16 on Nov. 29. Bellicum is developing novel cellular immunotherapies for...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.